Similarly, EGF can accelerate glucose intake and lactate release in breast cancer and in glioma cells, where EGF-mediated nuclear translocation of Pyruvate kinase muscle isozyme M2 (PKM2), a limiting glycolytic enzyme that catalyses the final step in glycolysis, induces tumourigenesis and cell proliferation [186]. Here, EGF is linked to breast carcinoma.